%PDF-1.4
%
26 0 obj
<>
endobj
23 0 obj
<>
endobj
73 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-21T15:09:53Z
2024-03-28T11:32-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T11:32-07:00
application/pdf
Heather
2003-167.aug.suppl.67
uuid:8cd21302-1dd2-11b2-0a00-c508278d5b00
uuid:8cd21305-1dd2-11b2-0a00-1e0000000000
endstream
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 4 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 6 0 R/Type/Page>>
endobj
80 0 obj
[85 0 R]
endobj
81 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
408 770 150 -25 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Hasegawa: Japan Rheumatism Friendship )18 (Association)]TJ
0 Tc 0 Tw 61.9375 -0.0313 Td
(49)Tj
/T1_1 1 Tf
-0.00011 Tc -0.0118 Tw 10 0 0 10 54 713.1616 Tm
[(story applies for new tumor necrosis factor)20 (-inhibiting drugs.)]TJ
0.0585 Tw 0 -1.2 TD
[(The JRF)74 (A)-254 (publishes information about clinical trials in our)]TJ
0.097 Tw T*
(magazine \322Nagare\323 to help recruit patients for enrollment.)Tj
0.1144 Tw T*
(One of our prime objectives is for Japan to catch up with)Tj
0.106 Tw T*
(other countries in terms of which drugs are authorized, so)Tj
0.0287 Tw T*
(that some of these promising new drugs can be made avail-)Tj
0.02499 Tw T*
[(able to arthritis suf)18 (ferers in Japan.)]TJ
-0.0173 Tw 1.2 -1.2 Td
(When asked what kind of developments they would most)Tj
0.0018 Tw -1.2 -1.2 Td
[(like to see in the area of rheumatology)65 (, the great majority of)]TJ
0.09531 Tw T*
(our members \321 some 85% \321 expressed the desire to see)Tj
0.162 Tw T*
(\322the cause of rheumatism clarified, and a clear course of)Tj
0.1644 Tw T*
(therapy established.\323 Indeed, if this could be achieved, it)Tj
0.1508 Tw T*
(would not be an exaggeration to say that we would have)Tj
0.0047 Tc 0.37019 Tw T*
[(reached our end goal. )18 (T)70 (wo years ago, after years of)]TJ
-0.00011 Tc 0.21111 Tw T*
[(campaigning and lobbying by the JRF)74 (A)-406 (and many other)]TJ
0.35719 Tw T*
(related groups, the long-awaited National Rheumatism-)Tj
0.3452 Tw T*
[(Aller)18 (gy Center was established. )18 (This development was)]TJ
0.0042 Tw T*
(especially remarkable in light of the current strain on public)Tj
0.1404 Tw T*
(finances accompanying the aging of Japanese society and)Tj
0.0107 Tw T*
[(the expanded role of the national health insurance or)18 (ganiza-)]TJ
0.0988 Tw T*
[(tion. )18 (The Center plans to conduct epidemiological surveys)]TJ
0.0199 Tc 0.43871 Tw T*
(via a nationwide network, develop new therapeutic)Tj
-0.00011 Tc 0.02499 Tw T*
(methods, and support clinical trials of new drugs.)Tj
0.194 Tw 27.6 26.4 Td
[(These ef)18 (forts are sure to contribute to a better under-)]TJ
0.106 Tw -1.2 -1.2 Td
(standing of the causes of rheumatism, and to facilitate the)Tj
0.03751 Tw T*
[(establishment of clear)20 (-cut therapies and treatments. Getting)]TJ
0.0755 Tw T*
[(the Center up and running has been one of the JRF)74 (A)111 (\325)55 (s key)]TJ
-0.01849 Tw T*
(goals for many years, and the significance of the Ministry of)Tj
0.0168 Tw T*
[(Health, Labour and )18 (W)80 (elfare\325)55 (s decision to establish it should)]TJ
0.02499 Tw T*
(prove enormous.)Tj
1.2 -1.2 Td
(I would like to add the following as our future issues.)Tj
0.1373 Tw -1.2 -1.2 Td
[(1.)-450 (T)70 (o study the latest training and treatment methods and)]TJ
0.0007 Tc 0.37421 Tw T*
(information related to patients on a global scale, and)Tj
-0.00011 Tc 0.3073 Tw T*
(actively encourage the Japanese government to provide)Tj
0.06329 Tw T*
(support in bringing both treatments and education in Japan)Tj
0.02499 Tw T*
(up to international levels.)Tj
0.07249 Tw T*
[(2.)-450 (T)70 (o create an open international communication network)]TJ
0.18159 Tw T*
(with other patient groups worldwide via the Internet and)Tj
0.02499 Tw T*
(other media.)Tj
0.03371 Tw T*
[(3.)-450 (T)70 (o take advantage of this International Conference as an)]TJ
0.17909 Tw T*
(opportunity to begin studying and examining methods of)Tj
0.02921 Tw T*
(raising funds for administrative operations and other activi-)Tj
0.1264 Tw T*
[(ties, and also as an opportunity to develop more ef)18 (fective)]TJ
0.02499 Tw T*
[(ways to promote awareness of the JRF)74 (A)111 (\325)55 (s activities.)]TJ
ET
0 0 0 0 k
420 777 137 -27 re
f*
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
6 0 obj
<>stream
8;Z]"N=LRp#_[L'(Z]_Iq,:K[PT&7-bC.cQ#[Y'A6rj6rH*`NoU*[D;$'gVeUemU'
YpR@[!*W,IME4r**n=#0?.T1>g8gM,d4HooU[0$TP3.&^&fum4iTP%
endstream
endobj
10 0 obj
[/Indexed/DeviceRGB 255 9 0 R]
endobj
9 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
36 0 obj
<>
endobj
35 0 obj
<>
endobj
50 0 obj
<>
endobj
79 0 obj
<>
endobj
30 0 obj
<>
endobj
45 0 obj
<>stream
H|TPW{FAdF (DDwDWQ~&:|f0OPAKQWb"(FUF`6lSuwϹ1l2?D~f61Z3^+0~Oۙ ܌h33Y34?ؐG~-߲t]F⸤mZ]fznz`nj9p>ڍ*nM>Eib:mrt*v$$pcX=ҫӄWN碹XUbtr<[hS2u*g)MNQUG'U_c:^W70L"Ex#j|ŰtۃaKaFbW0%x#~CĈED?<٤dH"Nl-ֈK2$_iA01{eg'nvZLx9a ?[&ZXͲ*ꗭ]6%t(fM6vs:C5T)Lce;T; JY6m|~RD#+yWcZ\fzq;bhWȬ
6'RħXJ.ZȩȆq)H`%f>犂=ѻEJDs:p